No insider purchase over the last 90 days. The latest, by EXACT SCIENCES CORP, was filed 13 Nov 2019.
This page follows insider dealings at Genomic Health Inc as filed with SEC (Form 4). The past year has been quiet: not a single insider filing for Genomic Health Inc. The previous disclosure was published on 14 November 2019.
Looking back to 2016, when coverage begins, insiders filed 3 purchases and 1,036 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
FY ended December 2018 · cache
25 of 1457 declarations
Genomic Health Inc is a genomic diagnostics company that provides tests to assist in clinical decision-making for cancer treatment. It is listed on the XNAS market.
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2018 | 394.1 m USD | 25.7 m USD | 0.68 USD | 10-K |
| Dec 2017 | 340.8 m USD | -3.9 m USD | -0.11 USD | 10-K |
| Dec 2016 | 327.9 m USD | -13.9 m USD | -0.42 USD | 10-K |
| Dec 2015 | 287.5 m USD | -33.3 m USD | n.d. | 10-K |
| Dec 2014 | 275.7 m USD | n.d. | -0.78 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.